Legacy Housing Corporation - Common Stock (LEGH)
26.00
0.00 (0.00%)
Legacy Housing Corp is a manufacturer and retailer of manufactured homes, primarily serving the affordable housing market in the United States
The company focuses on producing a diverse range of energy-efficient and customizable homes designed to meet the needs of various customers, including individuals, families, and retirees. In addition to home construction, Legacy Housing provides services related to land leasing and community management, positioning itself as a comprehensive player in the manufactured housing sector. Through its innovative designs and emphasis on quality, the company aims to enhance homeownership opportunities for a broad demographic.
![](https://cdn.benzinga.com/files/images/story/2024/03/18/image31_0.jpeg?width=1200&height=800&fit=crop)
Shares of Science Applications International Corporation (NYSESAIC) fell sharply during Monday’s session after the company reported financial fourth-quarter EPS below estimates.
Via Benzinga · March 18, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
LEGH stock results show that Legacy Housing missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Via InvestorPlace · March 15, 2024
![](https://cdn.benzinga.com/files/images/story/2023/earnings_image.jpeg?width=1200&height=800&fit=crop)
Companies Reporting Before The Bell • EHang Holdings (NASDAQEH) is expected to report quarterly loss at $0.10 per share on revenue of $7.83 million.
Via Benzinga · March 15, 2024
![](/next-assets/images/schema-image-default.png)
Via Benzinga · November 7, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
LEGH stock results show that Legacy Housing beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Via InvestorPlace · August 8, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
LEGH stock results show that Legacy Housing beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 9, 2024
![](https://cdn.benzinga.com/files/images/story/2024/03/28/snowflake_-_logo.jpg?width=1200&height=800&fit=crop)
Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades.
Via Benzinga · March 28, 2024
![](https://cdn.benzinga.com/files/images/story/2024/03/27/image9.jpg?width=1200&height=800&fit=crop)
Although U.S. stocks closed lower on Tuesday, there were a few notable insider trades.
Via Benzinga · March 27, 2024
![](https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 30, 2024
![](https://cdn.benzinga.com/files/images/story/2023/11/13/image12.jpg?width=1200&height=800&fit=crop)
The most overbought stocks in the consumer discretionary sector presents an opportunity to go short on these overvalued companies.
Via Benzinga · November 13, 2023
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 10, 2023
![](https://www.investors.com/wp-content/uploads/2017/11/stock-family-large-adobe.jpg)
American Homes holds the No. 4 rank among its peers in the 166-stock Finance-Property REITs industry group.
Via Investor's Business Daily · August 3, 2023
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_2.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · August 23, 2023
![](https://cdn.benzinga.com/files/images/story/2023/06/21/uber_-logo.jpg?width=1200&height=800&fit=crop)
Rosenblatt boosted the price target for Lumentum Holdings Inc. (NASDAQLITE) from $48 to $67. Rosenblatt analyst Mike Genovese maintained a Neutral rating. Lumentum shares fell 1.3% to $60.56 in pre-market trading.
Via Benzinga · June 21, 2023
![](https://cdn.benzinga.com/files/images/story/2023/03/16/image30.jpeg?width=1200&height=800&fit=crop)
Gainers Lipella Pharmaceuticals Inc. (NASDAQLIPO) shares jumped 40.2% to $2.5109 after the company announced the successful completion of a Phase 2A clinical trial evaluating the safety and efficacy of its drug candidate LP-10 for hemorrhagic cystitis.
Via Benzinga · March 16, 2023
![](https://cdn.benzinga.com/files/images/story/2023/03/16/image31_0.jpeg?width=1200&height=800&fit=crop)
U.S. stocks traded lower, with the Dow Jones dropping more than 250 points on Thursday. Here are some big stocks recording gains in today’s session.
Via Benzinga · March 16, 2023